Research and Markets: Pharmaceutical Cliff Diving - Assessing the Key Challenges that will Re-Shape the Industry in 2011

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/6ece8d/pharmaceutical_cli) has announced the addition of the "Pharmaceutical Cliff Diving - Assessing the Key Challenges that will Re-Shape the Industry" report to their offering.

In a challenging period for the pharmaceutical industry, first quarter results show an interesting picture. The generics industry, unsurprisingly, showed strong growth; lacking the impact of the patent cliff, the biotech industry also grew. For big pharma, sales were flat to negative for most, but a number of companies found that their work to streamline and restructure were showing positive results, with Q1 profits up.

The industry faces challenges from the government sector as well: increasing surveillance from the FDA, and the possibility of heightened penalties for pharma executives. Uncertainty over the direction of last year's Health Care Reform legislation also continues. From the Supreme Court, the industry has primarily found challenges overcome, with the Court upholding pay-for-delay, while striking down laws restricting prescription drug data-mining and pricing lawsuits.

Pharmaceutical Cliff Diving is a consultancy-style report which identifies, assesses, and provides insights on the key challenges that industry is experiencing now and in the near future. Through CBR Pharma Insights' unique report writing approach, companies will be able to analyze these key issues quickly and utilize our content to support their strategic decisions within multiple business units.

Reasons to Purchase

  • Compare first quarter results for the pharmaceutical industry to see how companies are holding up to the patent cliff
  • Investigate restructuring strategies in the face of the industry's obstacles
  • Assess the new challenges coming from FDA, and what they will mean for the pharmaceutical industry
  • Examine the hurdles in key emerging markets, as well as their potential
  • Analyze the direction pharma R&D will be taking in the future
  • Understand recent Supreme Court decisions that will impact your business & the pharmaceutical industry as a whole
  • To get the patients' perspective on the costs associated with current pharmaceutical treatments

Key Topics Covered:

Executive Summary

Early 2011 Results

  • Top big pharma companies
  • Top biotech companies
  • Top generics companies

White House and Congress

  • FDA
  • Forest Labs and the Medicare/Medicaid ban
  • Medicare off-label legislation
  • Health care reform

Supreme Court

  • Over-time pay
  • Pay-for-delay
  • Pricing
  • Prescription drug data-mining

The Patent Cliff & Industry Strategy

  • Impact of the patent cliff
  • Need for restructuring
  • Case studies: Pfizer & Merck
  • Pharma lay-offs
  • Sales force trends

Emerging Markets

  • Q1 results for emerging markets
  • Means of moving into emerging markets
  • China
  • India
  • Challenges companies face

Outlook for the Pharmaceutical Industry

  • The pharmaceutical industry consumer
  • Direction of US drug spending
  • Generics industry growth

Appendix

Total Report Size - 72 slides; fully sourced

For more information visit http://www.researchandmarkets.com/research/6ece8d/pharmaceutical_cli



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:

INDUSTRY KEYWORDS:   Health  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

After Purdue’s record opioid settlement, more deals could be on the way. But that doesn’t mean all defendants are prepared to go quietly.

Now in their third quarter on the market, Gilead's own Epclusa and Harvoni generics have together grabbed more than 20% of the U.S. hep C market.

Purdue is seeking bankruptcy after inking a $10 billion-plus opioid settlement with thousands of cities and counties, plus two dozen states.